ClinicalTrials.gg
CompletedNCT02817828Updated Oct 4, 2019Results posted

E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study

A Phase 3 interventional study of 15 mg E4/3 mg DRSP in Contraception, sponsored by Estetra. Completed at 1 site in Belgium. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-10-04.

Sponsored by Estetra · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,577
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

The objectives of this study are to evaluate the contraceptive efficacy, vaginal bleeding pattern (cycle control), and the general safety and acceptability of the 15 mg estetrol (E4)/3 mg drospirenone (DRSP) combination in healthy women aged 18 to 50 years.

02

Conditions studied

  • Contraception

Keywords

  • Estetrol
03

In context

Lead sponsor

Estetra is the lead sponsor of 15 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Heterosexually active female at risk for pregnancy and requesting .
  • Negative serum pregnancy test at subject enrollment.
  • Willing to use the product as the primary method of contraception for 13 consecutive cycles.
  • Good physical and mental health on the basis of medical, surgical and gynecological history, physical examination, gynecological examination, clinical laboratory, and vital signs.
  • (BMI) below or equal to (≤) 35.0 kg/m2.
  • Able to fulfill the requirements of the protocol and have indicated a willingness to participate in the study by providing written (IC).
  • Willing and able to complete the diaries and questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Known to any of the product ingredients.
  • Smoking if ≥ 35 years old, at screening.
  • Any condition associated with decrease fertility.
  • Dyslipoproteinemia requiring active treatment with antilipidemic agent.
  • Diabetes mellitus with vascular involvement (nephropathy, retinopathy, neuropathy, other) or diabetes mellitus of more than 20-year duration.
  • Arterial hypertension.
  • Any condition associated with an increased risk of venous thromboembolism and/or arterial thromboembolism.
  • Any condition associated with abnormal uterine/vaginal bleeding.
  • Abnormal Pap test based on current international recommendations.
  • Presence of an undiagnosed breast mass.
  • Current symptomatic gallbladder disease.
  • History of COC related cholestasis.
  • Presence or history of severe hepatic disease.
  • Presence or history of pancreatitis if associated with hypertriglyceridemia.
  • Porphyria.
  • Presence or history of hepatocellular adenoma or malignant liver tumors.
  • Renal impairment.
  • Hyperkaliemia or presence of conditions that predispose to hyperkaliemia.
  • Presence or history of hormone-related .
  • History of non-hormone-related malignancy within 5 years before screening. Subjects with a non-melanoma skin cancer are allowed in the study.
  • Use of drugs potentially triggering interactions with COCs.
  • History of alcohol or drug abuse (including laxatives) within 12 months prior to screening.
  • Any condition that could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the investigational product.
  • Uncontrolled thyroid disorders.
  • Participation in another investigational drug clinical study within 1 month (30 days) or have received an investigational drug within the last 3 months (90 days) prior to study entry. Subjects who participated in an oral clinical study, using FDA/EU approved active ingredients, may be enrolled 2 months (60 days) after completing the preceding study.
  • Sponsor, CRO or Investigator's site personnel directly affiliated with this study.
  • Is judged by the Investigator to be unsuitable for any reason.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,577 participants (actual)

Study arms

  • Experimental
    15 mg E4/3 mg DRSP

    15 mg E4/3 mg DRSP tablet

    Drug: 15 mg E4/3 mg DRSP

Interventions

  • Drug15 mg E4/3 mg DRSP

    Drug pages: Estetrol · Drospirenone

    15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.

    Also known as: 15 mg estetrol and 3 mg drospirenone

06

What researchers measure

Primary outcomes

  1. The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening

    On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment.Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.

    Time frame: Up to 12 months (13 cycles with 1 cycle = 28 days)

Secondary outcomes

  1. The Number of On-treatment Pregnancies (With 2-day Window) as Assessed by the Method Failure Pearl Index in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening

    On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment. The method failure Pearl Index includes only those pregnancies that were classified as method failure and not the pregnancies due to user failure, i.e. incorrect intake of the contraceptive method. Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.

    Time frame: Up to 12 months (13 cycles with 1 cycle = 28 days)

  2. The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in the Overall Study Population (18-50 Years)

    On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment.Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.

    Time frame: Up to 12 months (13 cycles with 1 cycle = 28 days)

  3. The Number of On-Treatment Pregnancies as Assessed by the Method Failure Pearl Index in the Overall Study Population (18-50 Years)

    On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment. The method failure Pearl Index includes only those pregnancies that were classified as method failure and not the pregnancies due to user failure, i.e. incorrect intake of the contraceptive method. Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.

    Time frame: Up to 12 months (13 cycles with 1 cycle = 28 days)

  4. Number of Subjects With Unscheduled Bleeding/Spotting

    Unscheduled bleeding/spotting is defined as any bleeding/spotting that occurs while taking active hormones that does not meet the criteria for scheduled bleeding.

    Time frame: Up to 11 months (12 cycles with 1 cycle = 28 days)

  5. Number of Unscheduled Bleeding Days Per Cycle

    Unscheduled bleeding is defined as any bleeding that occurs while taking active hormones that does not meet the criteria for scheduled bleeding and/or spotting.

    Time frame: Up to 11 months (12 cycles with 1 cycle = 28 days)

  6. Number of Unscheduled Spotting Days Per Cycle

    Unscheduled spotting is defined as any spotting that occurs while taking active hormones that does not meet the criteria for scheduled bleeding and/or spotting.

    Time frame: Up to 11 months (12 cycles with 1 cycle = 28 days)

  7. Number of Subjects With Absence of Scheduled Bleeding and/or Spotting

    Scheduled bleeding/spotting is defined as any bleeding/spotting that occurs during the hormone-free interval (i.e. Days 25 - 28) and continues through Days 1-3 of the subsequent active cycle.

    Time frame: Up to 11 months (12 cycles with 1 cycle = 28 days)

  8. Number of Scheduled Bleeding and/or Spotting Days Per Cycle

    Scheduled bleeding and /or spotting is defined as any bleeding and/or spotting that occurs during the hormone-free interval (i.e. Days 25 - 28) and continues through Days 1-3 of the subsequent active cycle.

    Time frame: Up to 11 months (12 cycles with 1 cycle = 28 days)

  9. Number of Subjects With Abnormal Vital Signs

    Vital signs included sitting systolic and diastolic blood pressures, and heart rate.

    Time frame: From screening to end of treatment (12 months)

  10. Number of Subjects With Abnormal Laboratory Assessment Results

    Laboratory assessment included blood hematology, biochemistry, and lipids

    Time frame: From screening to end of treatment (12 months)

  11. Number of Subjects With Abnormal Physical Examination Results

    Physical examinations included an evaluation of body as a whole, skin, head, eyes, ears, nose, and throat, neck, cardiovascular, respiratory, musculoskeletal, neurologic, lymphatic/thyroid, abdomen. When reporting the results of the physical examination, the use of the "Abnormal" category was reserved for findings that were considered clinically significant, in the opinion of the Investigator; the "Normal" category included "Abnormal" results that were not clinically significant, as well as no findings.

    Time frame: From screening to end of treatment (12 months)

  12. Number of Subjects With Abnormal Gynecological Examination Results

    Gynecological examinations included breast examination (performed by palpation) and assessment of the adnexa, cervix, uterus, vagina, and external genitalia. When reporting the results, the use of the "Abnormal" category was reserved for findings that were considered clinically significant, in the opinion of the Investigator; the "Normal" category included "Abnormal" results that were not clinically significant, as well as no findings.

    Time frame: From screening to end of treatment (12 months)

  13. Endometrial Biopsy Histology at Screening and End of Treatment

    Endometrial biopsies was obtained from a subset of subjects included in the endometrial safety substudy at the screening visit and at the end of treatment visit if the subject has completed at least 10 cycles.

    Time frame: Baseline and end of treatment (up to 13 cycles with 1 cycle = 28 days)

  14. Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Percentage Maximum (Sum of First 14 Items)

    The Q-LES-Q-SF is a self-report measure designed to assess the degree of enjoyment and satisfaction in daily functioning. Participants were asked to rate 16 different items on a 5-point scale where score 1 = very poor and score 5 = very good. A raw total score is calculated by summing the first 14 items and ranges from 14 to 70 with a higher scores indicating higher life enjoyment and satisfaction. The raw total score is then transformed into a percentage maximum score using the following formula: (raw total score-minimum score)/(maximum possible raw score-minimum score). In addition, the last two items (15 and 16) are two global items that are scored individually. These items rate "satisfaction with medicine" and "overall life satisfaction over the past week".

    Time frame: Baseline and Cycle 13 (1 cycle = 28 days)

  15. Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Satisfaction With Medicine and Overall Life Satisfaction Over the Past Week

    The Q-LES-Q-SF is a self-report measure designed to assess the degree of enjoyment and satisfaction in daily functioning. Participants were asked to rate 16 different items on a 5-point scale where score 1 = very poor and score 5 = very good. A raw total score is calculated by summing the first 14 items and ranges from 14 to 70 with a higher scores indicating higher life enjoyment and satisfaction. The raw total score is then transformed into a percentage maximum score using the following formula: (raw total score-minimum score)/(maximum possible raw score-minimum score). In addition, the last two items (15 and 16) are two global items that are scored individually. These items rate "satisfaction with medicine" and "overall life satisfaction over the past week".

    Time frame: Baseline and Cycle 13 (1 cycle = 28 days)

  16. Change From Baseline to End of Treatment in the Score of the Menstrual Distress Questionnaire (MDQ)

    The MDQ is a standard method for measuring cyclical perimenstrual symptoms. The participants rated common symptoms and feelings associated with menstruation using the following scale: 0 (no experience of symptom), 1 (present, mild), 2 (present, moderate), 3 (present, strong),and 4 (present, severe) observed during pre-menstrual (4 days before menstruation), menstrual (most recent flow) and intermenstrual (remainder of the cycle) phases. Reported values are values at Cycle 13 minus values at Baseline. An overall positive change from baseline represents an increase in symptom or feeling severity.

    Time frame: Baseline and Cycle 13 (1 cycle = 28 days)

07

Results

Posted Oct 4, 2019

Participant flow

Participant flow — Overall Study
Milestone15 mg E4/3 mg DRSP
Started1553
Completed1218
Not completed335
Withdrew: Lost to follow-up41
Withdrew: Adverse event not related to bleeding104
Withdrew: Adverse event related to bleeding53
Withdrew: Protocol violation11
Withdrew: Pregnancy7
Withdrew: Pregnancy wish15
Withdrew: Withdrawal by subject78
Withdrew: Other26

Outcome measures

PrimaryThe Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening

On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment.Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.

Time frame:
Up to 12 months (13 cycles with 1 cycle = 28 days)
Reported as:
Number · Pearl Index
The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening
Pearl Index15 mg E4/3 mg DRSP
The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening0.47 (0.15 to 1.11)
SecondaryThe Number of On-treatment Pregnancies (With 2-day Window) as Assessed by the Method Failure Pearl Index in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening

On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment. The method failure Pearl Index includes only those pregnancies that were classified as method failure and not the pregnancies due to user failure, i.e. incorrect intake of the contraceptive method. Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.

Time frame:
Up to 12 months (13 cycles with 1 cycle = 28 days)
Reported as:
Number · Method failure Pearl Index
The Number of On-treatment Pregnancies (With 2-day Window) as Assessed by the Method Failure Pearl Index in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening
Method failure Pearl Index15 mg E4/3 mg DRSP
The Number of On-treatment Pregnancies (With 2-day Window) as Assessed by the Method Failure Pearl Index in Subjects Aged 18 to 35 Years, Inclusive, at the Time of Screening0.29 (0.06 to 0.83)
SecondaryThe Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in the Overall Study Population (18-50 Years)

On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment.Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.

Time frame:
Up to 12 months (13 cycles with 1 cycle = 28 days)
Reported as:
Number · Pearl Index
The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in the Overall Study Population (18-50 Years)
Pearl Index15 mg E4/3 mg DRSP
The Number of On-treatment Pregnancies (With + 2-day Window) Per 100 Woman-years of Exposure (Pearl Index) in the Overall Study Population (18-50 Years)0.41 (0.13 to 0.96)
SecondaryThe Number of On-Treatment Pregnancies as Assessed by the Method Failure Pearl Index in the Overall Study Population (18-50 Years)

On-treatment pregnancies are defined as pregnancies with an estimated date of conception within the in-treatment period i.e. Day 1 to 2 days after the last intake of investigational product (whether active or inactive tablet). The Pearl Index, defined as the number of pregnancies per 100 women-years of treatment was calculated as: Pearl Index = (1300\*number of on-treatment pregnancies)/number of women 28-day equivalent cycles of treatment. The method failure Pearl Index includes only those pregnancies that were classified as method failure and not the pregnancies due to user failure, i.e. incorrect intake of the contraceptive method. Only at-risk cycles were included in the denominator of the Pearl Index calculation. At-risk-cycles were defined as cycles in which no other methods of birth control (including condoms) were used by the subject as confirmed in the subject diary and during which the subject confirmed that sexual intercourse had occurred.

Time frame:
Up to 12 months (13 cycles with 1 cycle = 28 days)
Reported as:
Number · Method Failure Pearl Index
The Number of On-Treatment Pregnancies as Assessed by the Method Failure Pearl Index in the Overall Study Population (18-50 Years)
Method Failure Pearl Index15 mg E4/3 mg DRSP
The Number of On-Treatment Pregnancies as Assessed by the Method Failure Pearl Index in the Overall Study Population (18-50 Years)0.25 (0.05 to 0.72)
SecondaryNumber of Subjects With Unscheduled Bleeding/Spotting

Unscheduled bleeding/spotting is defined as any bleeding/spotting that occurs while taking active hormones that does not meet the criteria for scheduled bleeding.

Time frame:
Up to 11 months (12 cycles with 1 cycle = 28 days)
Reported as:
Count of participants · Participants
Number of Subjects With Unscheduled Bleeding/Spotting
Participants15 mg E4/3 mg DRSP
Cycle 1354
Cycle 2282
Cycle 3250
Cycle 4249
Cycle 5238
Cycle 6207
Cycle 7170
Cycle 8202
Cycle 9182
Cycle 10168
Cycle 11155
Cycle 12154
SecondaryNumber of Unscheduled Bleeding Days Per Cycle

Unscheduled bleeding is defined as any bleeding that occurs while taking active hormones that does not meet the criteria for scheduled bleeding and/or spotting.

Time frame:
Up to 11 months (12 cycles with 1 cycle = 28 days)
Reported as:
Mean · Days
Number of Unscheduled Bleeding Days Per Cycle
Days15 mg E4/3 mg DRSP
Cycle 10.2 ± 0.89
Cycle 20.1 ± 0.66
Cycle 30.1 ± 0.67
Cycle 40.2 ± 0.79
Cycle 50.1 ± 0.70
Cycle 60.1 ± 0.80
Cycle 70.1 ± 0.68
Cycle 80.1 ± 0.72
Cycle 90.1 ± 0.70
Cycle 100.1 ± 0.61
Cycle 110.1 ± 0.72
Cycle 120.1 ± 0.68
SecondaryNumber of Unscheduled Spotting Days Per Cycle

Unscheduled spotting is defined as any spotting that occurs while taking active hormones that does not meet the criteria for scheduled bleeding and/or spotting.

Time frame:
Up to 11 months (12 cycles with 1 cycle = 28 days)
Reported as:
Mean · Days
Number of Unscheduled Spotting Days Per Cycle
Days15 mg E4/3 mg DRSP
Cycle 10.8 ± 1.99
Cycle 20.5 ± 1.50
Cycle 30.5 ± 1.46
Cycle 40.5 ± 1.55
Cycle 50.5 ± 1.35
Cycle 60.4 ± 1.24
Cycle 70.4 ± 1.17
Cycle 80.4 ± 1.19
Cycle 90.4 ± 0.13
Cycle 100.4 ± 1.25
Cycle 110.3 ± 1.18
Cycle 120.4 ± 1.23
SecondaryNumber of Subjects With Absence of Scheduled Bleeding and/or Spotting

Scheduled bleeding/spotting is defined as any bleeding/spotting that occurs during the hormone-free interval (i.e. Days 25 - 28) and continues through Days 1-3 of the subsequent active cycle.

Time frame:
Up to 11 months (12 cycles with 1 cycle = 28 days)
Reported as:
Count of participants · Participants
Number of Subjects With Absence of Scheduled Bleeding and/or Spotting
Participants15 mg E4/3 mg DRSP
Cycle 184
Cycle 290
Cycle 3105
Cycle 483
Cycle 591
Cycle 691
Cycle 790
Cycle 8103
Cycle 992
Cycle 1089
Cycle 1180
Cycle 1294
SecondaryNumber of Scheduled Bleeding and/or Spotting Days Per Cycle

Scheduled bleeding and /or spotting is defined as any bleeding and/or spotting that occurs during the hormone-free interval (i.e. Days 25 - 28) and continues through Days 1-3 of the subsequent active cycle.

Time frame:
Up to 11 months (12 cycles with 1 cycle = 28 days)
Reported as:
Mean · Days
Number of Scheduled Bleeding and/or Spotting Days Per Cycle
Days15 mg E4/3 mg DRSP
Cycle 16.1 ± 4.95
Cycle 25.3 ± 3.62
Cycle 35.2 ± 3.99
Cycle 45.0 ± 3.14
Cycle 54.9 ± 3.43
Cycle 64.9 ± 3.34
Cycle 74.7 ± 2.80
Cycle 84.8 ± 3.85
Cycle 94.7 ± 2.87
Cycle 104.6 ± 2.69
Cycle 114.7 ± 3.16
Cycle 124.6 ± 2.97
SecondaryNumber of Subjects With Abnormal Vital Signs

Vital signs included sitting systolic and diastolic blood pressures, and heart rate.

Time frame:
From screening to end of treatment (12 months)
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Vital Signs
Participants15 mg E4/3 mg DRSP
Number of Subjects With Abnormal Vital Signs15
SecondaryNumber of Subjects With Abnormal Laboratory Assessment Results

Laboratory assessment included blood hematology, biochemistry, and lipids

Time frame:
From screening to end of treatment (12 months)
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Laboratory Assessment Results
Participants15 mg E4/3 mg DRSP
Number of Subjects With Abnormal Laboratory Assessment Results55
SecondaryNumber of Subjects With Abnormal Physical Examination Results

Physical examinations included an evaluation of body as a whole, skin, head, eyes, ears, nose, and throat, neck, cardiovascular, respiratory, musculoskeletal, neurologic, lymphatic/thyroid, abdomen. When reporting the results of the physical examination, the use of the "Abnormal" category was reserved for findings that were considered clinically significant, in the opinion of the Investigator; the "Normal" category included "Abnormal" results that were not clinically significant, as well as no findings.

Time frame:
From screening to end of treatment (12 months)
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Physical Examination Results
Participants15 mg E4/3 mg DRSP
Body as a whole - Baseline — Normal1548
Body as a whole - Baseline — Abnormal5
Body as a whole - Baseline — Not done0
Body as a whole - EOT — Normal1493
Body as a whole - EOT — Abnormal5
Body as a whole - EOT — Not done0
Skin - Baseline — Normal1537
Skin - Baseline — Abnormal16
Skin - Baseline — Not done0
Skin - EOT — Normal1,476
Skin - EOT — Abnormal22
Skin - EOT — Not done0
Head, Eyes, Ears, Nose and Throat - Baseline — Normal1,543
Head, Eyes, Ears, Nose and Throat - Baseline — Abnormal10
Head, Eyes, Ears, Nose and Throat - Baseline — Not done0
Head, Eyes, Ears, Nose and Throat - EOT — Normal1,492
Head, Eyes, Ears, Nose and Throat - EOT — Abnormal3
Head, Eyes, Ears, Nose and Throat - EOT — Not done3
Neck - Baseline — Normal1,552
Neck - Baseline — Abnormal1
Neck - Baseline — Not done0
Neck - EOT — Normal1,495
Neck - EOT — Abnormal1
Neck - EOT — Not done2
Cardiovascular - Baseline — Normal1,553
Cardiovascular - Baseline — Abnormal0
Cardiovascular - Baseline — Not done0
Cardiovascular - EOT — Normal1,496
Cardiovascular - EOT — Abnormal1
Cardiovascular - EOT — Not done1
Respiratory - Baseline — Normal1,551
Respiratory - Baseline — Abnormal2
Respiratory - Baseline — Not done0
Respiratory - EOT — Normal1,496
Respiratory - EOT — Abnormal1
Respiratory - EOT — Not done1
Musculoskeletal - Baseline — Normal1,553
Musculoskeletal - Baseline — Abnormal0
Musculoskeletal - Baseline — Not done0
Musculoskeletal - EOT — Normal1,495
Musculoskeletal - EOT — Abnormal1
Musculoskeletal - EOT — Not done2
Neurologic - Baseline — Normal1,553
Neurologic - Baseline — Abnormal0
Neurologic - Baseline — Not done0
Neurologic - EOT — Normal1,494
Neurologic - EOT — Abnormal2
Neurologic - EOT — Not done2
Lymphatic/Thyroid - Baseline — Normal1,549
Lymphatic/Thyroid - Baseline — Abnormal2
Lymphatic/Thyroid - Baseline — Not done2
Lymphatic/Thyroid - EOT — Normal1,494
Lymphatic/Thyroid - EOT — Abnormal1
Lymphatic/Thyroid - EOT — Not done3
Abdomen - Baseline — Normal1,553
Abdomen - Baseline — Abnormal0
Abdomen - Baseline — Not done0
Abdomen - EOT — Normal1,496
Abdomen - EOT — Abnormal1
Abdomen - EOT — Not done1
SecondaryNumber of Subjects With Abnormal Gynecological Examination Results

Gynecological examinations included breast examination (performed by palpation) and assessment of the adnexa, cervix, uterus, vagina, and external genitalia. When reporting the results, the use of the "Abnormal" category was reserved for findings that were considered clinically significant, in the opinion of the Investigator; the "Normal" category included "Abnormal" results that were not clinically significant, as well as no findings.

Time frame:
From screening to end of treatment (12 months)
Reported as:
Count of participants · Participants
Number of Subjects With Abnormal Gynecological Examination Results
Participants15 mg E4/3 mg DRSP
Breast - Baseline — Normal1,545
Breast - Baseline — Abnormal8
Breast - Baseline — Not done0
Breast - EOT — Normal1,485
Breast - EOT — Abnormal13
Breast - EOT — Not done1
Adnexa - Baseline — Normal1,549
Adnexa - Baseline — Abnormal4
Adnexa - Baseline — Not done0
Adnexa - EOT — Normal1,496
Adnexa - EOT — Abnormal2
Adnexa - EOT — Not done1
Cervix - Baseline — Normal1,532
Cervix - Baseline — Abnormal21
Cervix - Baseline — Not done0
Cervix - EOT — Normal1,485
Cervix - EOT — Abnormal13
Cervix - EOT — Not done1
Uterus - Baseline — Normal1,542
Uterus - Baseline — Abnormal11
Uterus - Baseline — Not done0
Uterus - EOT — Normal1,492
Uterus - EOT — Abnormal6
Uterus - EOT — Not done1
Vagina - Baseline — Normal1,545
Vagina - Baseline — Abnormal8
Vagina - Baseline — Not done0
Vagina - EOT — Normal1,489
Vagina - EOT — Abnormal8
Vagina - EOT — Not done2
External genitalia - Baseline — Normal1,552
External genitalia - Baseline — Abnormal1
External genitalia - Baseline — Not done0
External genitalia - EOT — Normal1,497
External genitalia - EOT — Abnormal1
External genitalia - EOT — Not done1
SecondaryEndometrial Biopsy Histology at Screening and End of Treatment

Endometrial biopsies was obtained from a subset of subjects included in the endometrial safety substudy at the screening visit and at the end of treatment visit if the subject has completed at least 10 cycles.

Time frame:
Baseline and end of treatment (up to 13 cycles with 1 cycle = 28 days)
Reported as:
Count of participants · Participants
Endometrial Biopsy Histology at Screening and End of Treatment
Participants15 mg E4/3 mg DRSP
Baseline — No tissue0
Baseline — Tissue insufficient for diagnosis1
Baseline — Benign histology:Atrophic2
Baseline — Benign histology: Inactive7
Baseline — Benign histology:Proliferative76
Baseline — Secretory22
Baseline — Menstrual type0
Baseline — Simple hyperplasia without atypia0
Baseline — Complex hyperplasia without atypia0
Baseline — Pre-malignant/Malignant histology0
End of Treatment — No tissue0
End of Treatment — Tissue insufficient for diagnosis9
End of Treatment — Benign histology:Atrophic11
End of Treatment — Benign histology: Inactive61
End of Treatment — Benign histology:Proliferative22
End of Treatment — Secretory5
End of Treatment — Menstrual type0
End of Treatment — Simple hyperplasia without atypia0
End of Treatment — Complex hyperplasia without atypia0
End of Treatment — Pre-malignant/Malignant histology0
SecondaryQuality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Percentage Maximum (Sum of First 14 Items)

The Q-LES-Q-SF is a self-report measure designed to assess the degree of enjoyment and satisfaction in daily functioning. Participants were asked to rate 16 different items on a 5-point scale where score 1 = very poor and score 5 = very good. A raw total score is calculated by summing the first 14 items and ranges from 14 to 70 with a higher scores indicating higher life enjoyment and satisfaction. The raw total score is then transformed into a percentage maximum score using the following formula: (raw total score-minimum score)/(maximum possible raw score-minimum score). In addition, the last two items (15 and 16) are two global items that are scored individually. These items rate "satisfaction with medicine" and "overall life satisfaction over the past week".

Time frame:
Baseline and Cycle 13 (1 cycle = 28 days)
Reported as:
Mean · Percentage maximum score on a scale
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Percentage Maximum (Sum of First 14 Items)
Percentage maximum score on a scale15 mg E4/3 mg DRSP - Baseline Results15 mg E4/3 mg DRSP - End of Treatment Results
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Percentage Maximum (Sum of First 14 Items)73.4 ± 12.7773.8 ± 12.82
SecondaryQuality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Satisfaction With Medicine and Overall Life Satisfaction Over the Past Week

The Q-LES-Q-SF is a self-report measure designed to assess the degree of enjoyment and satisfaction in daily functioning. Participants were asked to rate 16 different items on a 5-point scale where score 1 = very poor and score 5 = very good. A raw total score is calculated by summing the first 14 items and ranges from 14 to 70 with a higher scores indicating higher life enjoyment and satisfaction. The raw total score is then transformed into a percentage maximum score using the following formula: (raw total score-minimum score)/(maximum possible raw score-minimum score). In addition, the last two items (15 and 16) are two global items that are scored individually. These items rate "satisfaction with medicine" and "overall life satisfaction over the past week".

Time frame:
Baseline and Cycle 13 (1 cycle = 28 days)
Reported as:
Mean · Units on a scale
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) Results at Baseline and End of Treatment - Satisfaction With Medicine and Overall Life Satisfaction Over the Past Week
Units on a scale15 mg E4/3 mg DRSP - Baseline Results15 mg E4/3 mg DRSP - End of Treatment Results
Satisfaction with medicine4.0 ± 0.784.0 ± 0.77
Overall life statisfaction over the past week4.0 ± 0.684.0 ± 0.70
SecondaryChange From Baseline to End of Treatment in the Score of the Menstrual Distress Questionnaire (MDQ)

The MDQ is a standard method for measuring cyclical perimenstrual symptoms. The participants rated common symptoms and feelings associated with menstruation using the following scale: 0 (no experience of symptom), 1 (present, mild), 2 (present, moderate), 3 (present, strong),and 4 (present, severe) observed during pre-menstrual (4 days before menstruation), menstrual (most recent flow) and intermenstrual (remainder of the cycle) phases. Reported values are values at Cycle 13 minus values at Baseline. An overall positive change from baseline represents an increase in symptom or feeling severity.

Time frame:
Baseline and Cycle 13 (1 cycle = 28 days)
Reported as:
Mean · units on a scale
Change From Baseline to End of Treatment in the Score of the Menstrual Distress Questionnaire (MDQ)
units on a scale15 mg E4/3 mg DRSP Tablet - Menstrual Phase15 mg E4/3 mg DRSP Tablet - Premenstrual Phase15 mg E4/3 mg DRSP Tablet - Intermenstrual Phase
Pain-0.4 ± 3.6-0.1 ± 2.96-0.1 ± 2.67
Water retention-0.1 ± 2.61-0.1 ± 2.570.0 ± 2.09
Autonomic reactions-0.1 ± 1.42-0.0 ± 1.30-0.0 ± 1.22
Negative affect-0.4 ± 4.90-0.3 ± 4.70-0.1 ± 3.93
Impaired concentration0.0 ± 2.67-0.0 ± 2.550.0 ± 2.23
Behaviour change-0.1 ± 2.86-0.1 ± 2.55-0.0 ± 1.99
Arousal-0.3 ± 3.46-0.3 ± 3.62-0.3 ± 3.91
Control0.0 ± 1.520.0 ± 1.570.0 ± 1.63

Adverse events

Collected over From screening to end of treatment (13 months). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
15 mg E4/3 mg DRSP0/1,553 (0%)13/1,553 (0.8%)784/1,553 (50.5%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
Event15 mg E4/3 mg DRSP
AppendicitisInfections and infestations2/1553
Spinal column injuryInjury, poisoning and procedural complications1/1553
ConcussionInjury, poisoning and procedural complications1/1553
Upper limb fractureInjury, poisoning and procedural complications1/1553
Migraine without auraNervous system disorders1/1553
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/1553
PyrexiaGeneral disorders1/1553
VertigoEar and labyrinth disorders1/1553
Abdominal painGastrointestinal disorders1/1553
ColitisGastrointestinal disorders1/1553
Most frequent other events
Showing 10 of 30
Most frequent other events
Event15 mg E4/3 mg DRSP
HeadacheNervous system disorders120/1553
MetrorrhagiaReproductive system and breast disorders85/1553
Vaginal haemorrhageReproductive system and breast disorders74/1553
AcneSkin and subcutaneous tissue disorders65/1553
DysmenorrhoeaReproductive system and breast disorders47/1553
Breast painReproductive system and breast disorders42/1553
Libido decreasedNervous system disorders38/1553
Weight increasedInvestigations36/1553
Abdominal painGastrointestinal disorders36/1553
Urinary tract infectionInfections and infestations30/1553

Baseline characteristics

All participants aged 18 to 50 years who received at least one dose of 15 mg E4/3 mg DRSP

Age, Categorical
Age, Categorical(Participants)15 mg E4/3 mg DRSP
<=18 years0
Between 18 and 65 years1,553
>=65 years0
Age, Continuous
Age, Continuous(years)15 mg E4/3 mg DRSP
Mean27.1 ± 6.86
Sex: Female, Male
Sex: Female, Male(Participants)15 mg E4/3 mg DRSP
Female1,553
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)15 mg E4/3 mg DRSP
Hispanic or Latino13
Not Hispanic or Latino1540
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)15 mg E4/3 mg DRSP
Belgium87
Czechia335
Finland181
Germany141
Hungary190
Norway108
Poland221
Russia280
Sweden10
Body mass index
Body mass index(Kg/m^2)15 mg E4/3 mg DRSP
Mean23.0 ± 3.469
08

Study locations

1 site
  • Hopital Saint-Pierre
    Bruxelles, 1000, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Apr 2018 and a completion of Apr 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2016
First posted
Jun 29, 2016
Start
Jun 2016
Primary completionActual
Apr 26, 2018
CompletionActual
Apr 26, 2018
Results first posted
Oct 4, 2019
Last update
Oct 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02817828
Lead sponsor
Estetra
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
Jun 29, 2016
Start date
Jun 2016
Primary completion
Apr 26, 2018
Completion
Apr 26, 2018
Results posted
Oct 4, 2019
Last update
Oct 4, 2019

Study contacts

Estetra
study director · Estetra

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estetrol · Drospirenone

Start the discussion